Jennifer Grancio Appointed to MannKind Board of Directors
March 24 2020 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer
Grancio has been appointed to its Board of Directors, effective
March 23, 2020. Ms. Grancio will also serve as a member of the
Audit Committee of the Board. Ms. Grancio brings to MannKind over
twenty years of financial services experience and an expertise in
creating disruptive business models.
“We are excited to welcome Ms. Grancio and her
years of invaluable leadership to our board of directors,” said
Kent Kresa, Chairman of the Board. “Her financial services
leadership experience will be an essential asset for MannKind as
the company continues to grow. We are committed to surrounding
ourselves with the best talent available, and the appointment of
Ms. Grancio reflects that effort.”
Ms. Grancio served as a founder and executive
with BlackRock’s iShares business from 1999 to 2018. She
spearheaded the distribution of iShares in the United States and
Europe and acted as the Global Head of Marketing and Partnerships
for BlackRock’s indexing service. Through those efforts, Ms.
Grancio established herself as a global leader in exchange-traded
and mutual funds.
Since her time at BlackRock, she founded Grancio
Capital, where she consults with company leaders on the best ways
to expand market reach and how to build effective teams to do so.
Previously, she was a senior associate with PricewaterhouseCoopers,
a management consulting firm.
Ms. Grancio has served as a board member for
Ethic, a sustainable investing firm, since November 2019. She
serves on the board of Harvest Savings & Wealth as of Q1 2020
and is on the advisory boards of Say Technologies and m+ funds. Ms.
Grancio is also active as a strategic advisor and speaker to
organizations that are committed to developing diverse senior
leaders and to developing leadership in young women.
She earned a bachelor’s degree in economics and
international relations from Stanford University, and an MBA degree
in strategy and finance from Columbia Business School.
With the addition of Ms. Grancio, there are nine
members of the MannKind Board of Directors.
About MannKind
CorporationMannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company’s first
FDA-approved product and the only inhaled ultra rapid-acting
mealtime insulin in the United States, where it is available by
prescription from pharmacies nationwide. MannKind is headquartered
in Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. Words such as "believes," "anticipates,"
"plans," "expects," "intends," "will," "goal," "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based
upon MannKind's current expectations. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties detailed in MannKind's filings with
the SEC. For a discussion of these and other factors, please
refer to MannKind’s annual report on Form 10-K for the year
ended December 31, 2019 as well as MannKind’s other filings
with the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement,
and MannKind undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date of this press release.
Company
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024